Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA
October 25, 2022 at 14:26 PM EDT
The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial.
